规格: | 98% |
分子量: | 425.52 |
包装 | 价格(元) |
1mg | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
Background:
PU 23 is a Multidrug resistance protein 4 (MRP4/ABCC4) inhibitor. MRP4 is an ATP-binding cassette (ABC) transporter. It is associated with multidrug resistance (MDR), which is becoming a growing challenge to the treatment of cancer and infections[1].
Then compound?PU 23?was discovered to improve HEK293/MRP4 cell sensibility to 6-MP dramatically, and low concentration?PU 23?(5 μM) achieved the equivalent effect of 50 μM MK571. The accumulation of 6-MP was determined by validated high-performance liquid chromatography methods, and pretreatment of the HEK293/MRP4 cells with 50 μM MK571 or?PU 23?resulted in significantly increased accumulation of 6-MP by approximately 1.5 times. This compound was first reported with a novel scaffold compared with previously known MRP4 inhibitors, which is a hopeful molecular tool that can be used for overcoming multidrug resistance research[2].
参考文献:
[1]: Chen Y, Yuan X, et al. Discovery of novel multidrug resistance protein 4 (MRP4) inhibitors as active agents reducing resistance to anticancer drug 6-Mercaptopurine (6-MP) by structure and ligand-based virtual screening. PLoS One. 2018 Oct 15;13(10):e0205175.?
Protocol:
Cell experiment [1]: | |
Cell lines | HEK293/MRP4 cell line |
Preparation Method | MRP4 was overexpressed in the HEK293/MRP4 cell line. The PU 23 compounds in the presence of 6-MP(15 μM), using MK571 as the positive control.?Cell viability was assessed using sulforhodamine B (SRB) |
Reaction Conditions | 10 μM PU 23 for 72h. |
Applications | PU 23?showed the highest activity with an inhibition rate of 81.71% at the concentration of 10 μM with 6-MP and only 15.26% without 6-MP.?It increased cell sensitivity to 6-MP, but not toxic on its own. |
参考文献: [1]. Chen Y, Yuan X, et al. Discovery of novel multidrug resistance protein 4 (MRP4) inhibitors as active agents reducing resistance to anticancer drug 6-Mercaptopurine (6-MP) by structure and ligand-based virtual screening. PLoS One. 2018 Oct 15;13(10):e0205175.? |